Johnson & Johnsons 152B Trading Volume Ranks 32nd as It Commits 2 Billion to U.S. Manufacturing Expansion

On August 21, 2025, Johnson & Johnson (JNJ) traded with a volume of $1.52 billion, ranking 32nd in market activity. The stock closed up 0.05%, reflecting cautious optimism amid strategic corporate developments.

Johnson & Johnson announced a $2 billion investment in North Carolina to expand its U.S. manufacturing capabilities. This move follows growing uncertainty over potential pharmaceutical import tariffs proposed by the Trump administration, which could escalate to 250% over time. The company signed a 10-year agreement with Fujifilm Diosynth to utilize a 160,000-square-foot facility in Holly Springs, North Carolina, creating approximately 120 jobs. This agreement builds on Fujifilm’s prior $3 billion partnership with Regeneron for U.S. manufacturing at the same site.

The healthcare giant also indicated plans to announce additional U.S. manufacturing facilities in the coming months. These commitments align with its broader strategy to increase U.S. investments by 25% over four years, including a separate plant in Wilson, North Carolina, as disclosed in March. Analysts noted that the move positions J&J to mitigate risks from regulatory shifts while strengthening domestic supply chains.

Market participants highlighted the strategic importance of the investment amid sector-wide cost pressures. Public sentiment on social platforms reflected mixed views, with some observers questioning the long-term impact of tariffs on employment and others viewing the move as a proactive response to geopolitical uncertainties. The company’s focus on U.S. manufacturing expansion underscores its alignment with broader industry trends to localize production.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 1.98%, with a total return of 7.61% over 365 days. The strategy's Sharpe ratio was 0.94, indicating good risk-adjusted returns. However, the maximum drawdown of -29.16% shows the strategy's vulnerability during market downturns.